Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNZ-2566 (Trofinetide) in Pediatric Rett Syndrome
NCT02715115Phase 2Completed
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Rett syndrome (RTT) comparing NNZ-2566 with Placebo (2 arms). Primary endpoint: Adverse events at 11 weeks. Started Mar 2016; status: completed.
02
Drugs
trofinetide
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT02715115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715115.